

Nicola A Hanania

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8659176/nicola-a-hanania-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

264
papers

12,633
citations

54
h-index

105
g-index

345
ext. papers

15,109
ext. citations

4
avg, IF

6.41
L-index

#	Paper	IF	Citations
264	Management of Life-Threatening Asthma: Severe Asthma Series.. <i>Chest</i> , 2022 ,	5.3	3
263	The effectiveness of pulmonary rehabilitation on chronic obstructive pulmonary disease patients with concurrent presence of comorbid depression and anxiety.. <i>Respiratory Medicine</i> , 2022 , 197, 106850	4.6	4
262	Depressive and anxiety symptoms in patients with COPD: A network analysis.. <i>Respiratory Medicine</i> , 2022 , 198, 106865	4.6	2
261	Reducing the hidden burden of severe asthma: recognition and referrals from primary practice. <i>Journal of Asthma</i> , 2021 , 58, 849-854	1.9	0
260	Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. <i>Intensive Care Medicine</i> , 2021 , 47, 1258-1270	14.5	19
259	The impact of fungal allergic sensitization on asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2021 , 27, 3-8	3	4
258	Asthma and severe acute respiratory syndrome coronavirus 2019: current evidence and knowledge gaps. <i>Current Opinion in Pulmonary Medicine</i> , 2021 , 27, 45-53	3	10
257	Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies. <i>International Journal of COPD</i> , 2021 , 16, 865-875	3	1
256	Esomeprazole attenuates inflammatory and fibrotic response in lung cells through the MAPK/Nrf2/HO1 pathway. <i>Journal of Inflammation</i> , 2021 , 18, 17	6.7	3
255	Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials. <i>International Journal of COPD</i> , 2021 , 16, 1925-1938	3	
254	EAACI Biologicals Guidelines-Recommendations for severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021 , 76, 14-44	9.3	48
253	Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial. <i>Chest</i> , 2021 , 159, 985-995	5.3	2
252	Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 69-84	35.1	53
251	Long-Term Benefits of Pulmonary Rehabilitation in Patients With COPD: A 2-Year Follow-Up Study. <i>Chest</i> , 2021 , 159, 967-974	5.3	5
250	How to Assess Effectiveness of Biologics for Asthma and What Steps to Take When There Is Not Benefit. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021 , 9, 1081-1088	5.4	8
249	Dual-combination maintenance inhaler preferences in asthma and chronic obstructive pulmonary disease: A patient-centered benefit-risk assessment. <i>Respiratory Medicine</i> , 2021 , 176, 106278	4.6	1
248	Association of mild cognitive impairment and characteristic of COPD and overall health status in a cohort study. <i>Expert Review of Respiratory Medicine</i> , 2021 , 15, 153-159	3.8	4

247	Omalizumab in Asthma with Fixed Airway Obstruction: Post Hoc Analysis of EXTRA. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021 ,	5.4	2
246	Clinically Significant and Comorbid Anxiety and Depressive Symptoms Predict Severe Respiratory Exacerbations in Smokers: A Post-Hoc Analysis of the COPDGene and SPIROMICS Cohorts. <i>Annals of the American Thoracic Society</i> , 2021 ,	4.7	1
245	Treating COPD Patients with Inhaled Medications in the Era of COVID-19 and Beyond: Options and Rationales for Patients at Home. <i>International Journal of COPD</i> , 2021 , 16, 2687-2695	3	1
244	Revisiting Mild Asthma: Current Knowledge and Future Needs. <i>Chest</i> , 2021 ,	5.3	1
243	Association of Triglyceride-Glucose Index and Lung Health: A Population-Based Study. <i>Chest</i> , 2021 , 160, 1026-1034	5.3	3
242	Association of Systemic Inflammation with Depressive Symptoms in Individuals with COPD. <i>International Journal of COPD</i> , 2021 , 16, 2515-2522	3	3
241	Severe Glutathione Deficiency, Oxidative Stress and Oxidant Damage in Adults Hospitalized with COVID-19: Implications for GlyNAC (Glycine and -Acetylcysteine) Supplementation.. <i>Antioxidants</i> , 2021 , 11,	7.1	9
240	Managing hospitalized patients with a COPD exacerbation: the role of hospitalists and the multidisciplinary team.. <i>Postgraduate Medicine</i> , 2021 , 1-8	3.7	
239	COVID-19, asthma, and biological therapies: What we need to know. <i>World Allergy Organization Journal</i> , 2020 , 13, 100126	5.2	64
238	Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD. <i>ERJ Open Research</i> , 2020 , 6,	3.5	3
237	Prospective, Single-Arm, Longitudinal Study of Biomarkers in Real-World Patients with Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020 , 8, 2630-2639.e6	5.4	7
236	Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2020 , 125, 565-576.e1	3.2	17
235	Design of a home-based intervention for Houston-area African-American adults with asthma: Methods and lessons learned from a pragmatic randomized trial. <i>Contemporary Clinical Trials</i> , 2020 , 91, 105977	2.3	2
234	Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020 , 75, 1058-1068	9.3	36
233	Diagnosis and Management of Pulmonary Hypertension in Patients With CKD. <i>American Journal of Kidney Diseases</i> , 2020 , 75, 935-945	7.4	10
232	Maintenance inhaler therapy preferences of patients with asthma or chronic obstructive pulmonary disease: a discrete choice experiment. <i>Thorax</i> , 2020 , 75, 735-743	7.3	10
231	Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020 , 75, 1023-1042	9.3	90
230	Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020 , 75, 1043-1057	9.3	39

229	Eosinophilic vs. Neutrophilic Asthma. <i>Current Pulmonology Reports</i> , 2020 , 9, 28-35	0.5	0
228	and its IgE-inducing enterotoxins in asthma: current knowledge. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	32
227	Determinants of lung function improvement with omalizumab in adults with allergic asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020 , 8, 2068-2070	5.4	3
226	A Risk Prediction Model for Mortality Among Smokers in the COPDGeno Study. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2020 , 7, 346-361	2.7	3
225	Revisiting Late-Onset Asthma: Clinical Characteristics and Association with Allergy. <i>Journal of Asthma and Allergy</i> , 2020 , 13, 743-752	3.1	1
224	Practical Considerations in Management of Allergic Asthma. <i>Respiratory Medicine</i> , 2020 , 155-180	0.2	
223	Disease Progression Modeling in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 201, 294-302	10.2	20
222	Severe Asthma and Biological Therapy: When, Which, and for Whom. <i>Pulmonary Therapy</i> , 2020 , 6, 47-66	3	26
221	The Hospital Readmissions Reduction Program and Readmissions for Chronic Obstructive Pulmonary Disease, 2006-2015. <i>Annals of the American Thoracic Society</i> , 2020 , 17, 450-456	4.7	15
220	Precision medicine and treatable traits in chronic airway diseases - where do we stand?. <i>Current Opinion in Pulmonary Medicine</i> , 2020 , 26, 33-39	3	6
219	Biomarkers of Type 2 Airway Inflammation as Predictors of Loss of Asthma Control During Step-Down Therapy for Well-Controlled Disease: The Long-Acting Beta-Agonist Step-Down Study (LASST). <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020 , 8, 3474-3481	5.4	2
218	Bayesian inference of networks across multiple sample groups and data types. <i>Biostatistics</i> , 2020 , 21, 561-576	3.7	5
217	Omaliuzumab Treatment Patterns Among Patients with Asthma in the US Medicare Population. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020 , 8, 507-515.e10	5.4	7
216	Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020 , 8, 516-526	5.4	61
215	The many faces of asthma-chronic obstructive pulmonary disease overlap. <i>Current Opinion in Pulmonary Medicine</i> , 2019 , 25, 1-10	3	9
214	Cost-effectiveness of fractional exhaled nitric oxide (FeNO) measurement in predicting response to omalizumab in asthma. <i>ClinicoEconomics and Outcomes Research</i> , 2019 , 11, 301-307	1.7	5
213	Targeting IL-5 in COPD. <i>International Journal of COPD</i> , 2019 , 14, 1045-1051	3	17
212	Activity-related dyspnea in chronic obstructive pulmonary disease: physical and psychological consequences, unmet needs, and future directions. <i>International Journal of COPD</i> , 2019 , 14, 1127-1138	3	35

211	Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. <i>Respiratory Medicine</i> , 2019 , 154, 86-92	4.6	13
210	Dupilumab Improves Lung Function and Reduces Severe Exacerbation Rate in Patients With Uncontrolled, Moderate-to-Severe Asthma With or Without Comorbid Allergic Rhinitis: Results From the Phase 3 LIBERTY ASTHMA QUEST Study. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 143, AB97	11.5	6
209	Targeting lipid mediators in asthma: time for reappraisal. <i>Current Opinion in Pulmonary Medicine</i> , 2019 , 25, 121-127	3	9
208	Dupilumab Suppresses Inflammatory Biomarkers in Asthma Patients With or Without Allergic Rhinitis: Post Hoc Analysis of the LIBERTY ASTHMA QUEST Study. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 143, AB97	11.5	6
207	Novel therapeutic targets and drug development for the precision treatment of COPD. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019 , 4, 121-128	1.6	3
206	The St. George's Respiratory Questionnaire Definition of Chronic Bronchitis May Be a Better Predictor of COPD Exacerbations Compared With the Classic Definition. <i>Chest</i> , 2019 , 156, 685-695	5.3	19
205	Radiation-Induced Lung Injury: Assessment and Management. <i>Chest</i> , 2019 , 156, 150-162	5.3	145
204	Combined Forced Expiratory Volume in 1 Second and Forced Vital Capacity Bronchodilator Response, Exacerbations, and Mortality in Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2019 , 16, 826-835	4.7	18
203	Controversies in Allergy: Should Severe Asthma with Eosinophilic Phenotype Always Be Treated with Anti-IL-5 Therapies. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019 , 7, 1430-1436	5.4	1
202	Clinical Approach to the Therapy of Asthma-COPD Overlap. <i>Chest</i> , 2019 , 155, 168-177	5.3	26
201	Clinical Epidemiology of COPD: Insights From 10 Years of the COPD Gene Study. <i>Chest</i> , 2019 , 156, 228-238	3.3	29
200	The responsiveness of the Manchester Chronic Obstructive Pulmonary Disease Fatigue Scale to pulmonary rehabilitation. <i>Therapeutic Advances in Chronic Disease</i> , 2019 , 10, 2040622319882206	4.9	2
199	Biologics targeting type 2 inflammation in severe asthma 2019 , 285-303		1
198	COPD Gene 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2019 , 6, 384-399	2.7	61
197	Novel and Alternative Therapies for Asthma in Older Adults 2019 , 135-153		
196	DUPILUMAB REDUCES SEVERE ASTHMA EXACERBATION RATE AND IMPROVES LUNG FUNCTION REGARDLESS OF AGE AT ONSET OF ASTHMA: THE LIBERTY ASTHMA QUEST STUDY. <i>Chest</i> , 2019 , 156, A936-A939	5.3	2
195	Immunological biomarkers in severe asthma. <i>Seminars in Immunology</i> , 2019 , 46, 101332	10.7	16
194	Response. <i>Chest</i> , 2019 , 156, 1276	5.3	

193	Biological treatments for severe asthma. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2019 , 19, 379-386	3.3	12
192	Symptoms of anxiety and depression and use of anxiolytic-hypnotics and antidepressants in current and former smokers with and without COPD - A cross sectional analysis of the COPDGene cohort. <i>Journal of Psychosomatic Research</i> , 2019 , 118, 18-26	4.1	12
191	Validity and Responsiveness of the Depression Anxiety Stress Scales-21 (DASS-21) in COPD. <i>Chest</i> , 2019 , 155, 1166-1177	5.3	22
190	Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 143, 1629-1633.e2	11.5	27
189	Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD. <i>International Journal of COPD</i> , 2019 , 14, 117-127	3	1
188	Measurement of fractional exhaled nitric oxide in real-world clinical practice alters asthma treatment decisions. <i>Annals of Allergy, Asthma and Immunology</i> , 2018 , 120, 414-418.e1	3.2	17
187	Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic Review. <i>Drug Safety</i> , 2018 , 41, 489-509	5.1	28
186	Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. <i>Journal of Allergy and Clinical Immunology</i> , 2018 , 141, 2037-2047.e10	11.5	95
185	Results of a Patient Survey Regarding COPD Knowledge, Treatment Experiences, and Practices With Inhalation Devices. <i>Respiratory Care</i> , 2018 , 63, 833-839	2.1	18
184	How does race/ethnicity influence pharmacological response to asthma therapies?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 435-446	5.5	13
183	Controversies and opportunities in severe asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2018 , 24, 83-93	3	9
182	Step-Down Therapy for Asthma Well Controlled on Inhaled Corticosteroid and Long-Acting Beta-Agonist: A Randomized Clinical Trial. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018 , 6, 633-643.e1	5.4	13
181	Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs. <i>Current Opinion in Pulmonary Medicine</i> , 2018 , 24, 50-55	3	35
180	Lobar Emphysema Distribution Is Associated With 5-Year Radiological Disease Progression. <i>Chest</i> , 2018 , 153, 65-76	5.3	23
179	Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial. <i>International Journal of COPD</i> , 2018 , 13, 499-508	3	2
178	Test Performance Characteristics of the AIR, GAD-7, and HADS-Anxiety Screening Questionnaires for Anxiety in Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2018 , 15, 926-934	4.7	20
177	Longitudinal Phenotypes and Mortality in Preserved Ratio Impaired Spirometry in the COPDGene Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 1397-1405	10.2	59
176	The Role of Inhalation Delivery Devices in COPD: Perspectives of Patients and Health Care Providers. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2018 , 5, 111-123	2.7	25

175	Anxiety and Depression in Chronic Obstructive Pulmonary Disease: Recognition and Management. <i>Cleveland Clinic Journal of Medicine</i> , 2018 , 85, S11-S18	2.8	31
174	Factors associated with depressive symptoms in uncontrolled asthmatics. <i>Journal of Asthma</i> , 2018 , 55, 555-560	1.9	4
173	Confronting the Challenge of COPD: What Is New in the Approaches to Diagnosis, Treatment, and Patient Outcomes. <i>Chest</i> , 2018 , 154, 984-985	5.3	3
172	Severe Acute Asthma 2018 , 391-402		
171	Impact of doxofylline compared to theophylline in asthma: A pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomized studies (DOROTHEO 1 and DOROTHEO 2). <i>Pulmonary Pharmacology and Therapeutics</i> , 2018 , 53, 20-26	3.5	15
170	New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology. <i>International Journal of COPD</i> , 2018 , 13, 2805-2819	3	5
169	Results of a Pulmonologist Survey Regarding Knowledge and Practices With Inhalation Devices for COPD. <i>Respiratory Care</i> , 2018 , 63, 840-848	2.1	7
168	COPD in Primary Care: Key Considerations for Optimized Management: Anxiety and Depression in Chronic Obstructive Pulmonary Disease: Recognition and Management. <i>Journal of Family Practice</i> , 2018 , 67, S11-S18	0.2	9
167	COPD Management in the Primary Care Setting. <i>Journal of Family Practice</i> , 2018 , 67, S27-S32	0.2	
166	Factors Determining In Vitro Lung Deposition of Albuterol Aerosol Delivered by Ventolin Metered-Dose Inhaler. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2017 , 30, 256-266	3.8	14
165	Assessing Patient and Provider Perceptions of Factors Associated with Patient Engagement in Asthma Care. <i>Annals of the American Thoracic Society</i> , 2017 , 14, 659-666	4.7	3
164	Safety of inhaled long-acting anti-muscarinic agents in COPD. <i>Postgraduate Medicine</i> , 2017 , 129, 500-513.	3.7	2
163	Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension Delivery Technology in patients with chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2017 , 126, 105-115	4.6	58
162	Fungal Sensitization Is Associated with Increased Risk of Life-Threatening Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017 , 5, 1025-1031.e2	5.4	25
161	Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. <i>Clinical and Experimental Allergy</i> , 2017 , 47, 161-175	4.1	199
160	Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 324-330	10.2	140
159	Obesity modulates diaphragm curvature in subjects with and without COPD. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2017 , 313, R620-R629	3.2	12
158	Predictive Biomarkers for Asthma Therapy. <i>Current Allergy and Asthma Reports</i> , 2017 , 17, 69	5.6	35

157	Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD. <i>Expert Opinion on Emerging Drugs</i> , 2017 , 22, 285-299	3.7	2
156	Effect of Yoga Breathing (Pranayama) on Exercise Tolerance in Patients with Chronic Obstructive Pulmonary Disease: A Randomized, Controlled Trial. <i>Journal of Alternative and Complementary Medicine</i> , 2017 , 23, 696-704	2.4	31
155	The Association of Depressive Symptoms With Rates of Acute Exacerbations in Patients With COPD: Results From a 3-year Longitudinal Follow-up of the ECLIPSE Cohort. <i>Journal of the American Medical Directors Association</i> , 2017 , 18, 955-959.e6	5.9	15
154	Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017 , 14, 552-563	2	61
153	Trends in 30-day readmission rates after COPD hospitalization, 2006-2012. <i>Respiratory Medicine</i> , 2017 , 130, 92-97	4.6	33
152	Role of biologics targeting type 2 airway inflammation in asthma: what have we learned so far?. <i>Current Opinion in Pulmonary Medicine</i> , 2017 , 23, 3-11	3	21
151	Characteristics and outcomes of older adults with long-standing versus late-onset asthma. <i>Journal of Asthma</i> , 2017 , 54, 223-229	1.9	12
150	Obesity Is Associated With Increased Morbidity in Moderate to Severe COPD. <i>Chest</i> , 2017 , 151, 68-77	5.3	66
149	Examining the Effects of Age on Health Outcomes of Chronic Obstructive Pulmonary Disease: Results From the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease Study and Evaluation of Chronic Obstructive Pulmonary Disease Longitudinally to Identify Predictive Surrogate Endpoints Cohort. <i>Journal of the American Medical Directors Association</i> , 2017 , 18, 1063-1068	5.9	5
148	Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. <i>Lancet Respiratory Medicine</i> , 2016 , 4, 781-796	35.1	302
147	An Official American Thoracic Society Workshop Report: Evaluation and Management of Asthma in the Elderly. <i>Annals of the American Thoracic Society</i> , 2016 , 13, 2064-2077	4.7	57
146	Measuring Competence in Metered Dose Inhaler Use Using Capmedic Electronic Inhaler Monitoring Tool. <i>Chest</i> , 2016 , 150, 14A	5.3	6
145	Rapid Lung Function Improvement with Lebrikizumab in Patients with Uncontrolled Asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2016 , 137, AB13	11.5	2
144	Assessing biomarkers in a real-world severe asthma study (ARIETTA). <i>Respiratory Medicine</i> , 2016 , 115, 7-12	4.6	13
143	Long-term Course of Depression Trajectories in Patients With COPD: A 3-Year Follow-up Analysis of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints Cohort. <i>Chest</i> , 2016 , 149, 916-26	5.3	38
142	Differences between absolute and predicted values of forced expiratory volumes to classify ventilatory impairment in chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2016 , 111, 30-8	4.6	5
141	IgE-mediated asthma: New revelations and future insights. <i>Respiratory Medicine</i> , 2016 , 112, 128-9	4.6	13
140	Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD. <i>PLoS Genetics</i> , 2016 , 12, e1006011	6	64

139	Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2016 , 4, 7-20	2.7	6
138	Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspension□ Delivery Technology Versus Foradil□ Aerolizer□ in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2016 , 4, 21-33	2.7	5
137	Asthma and Aging 2016 , 397-428		
136	Role of T2 inflammation biomarkers in severe asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2016 , 22, 59-68	3	47
135	Persistent and Newly Developed Chronic Bronchitis Are Associated with Worse Outcomes in Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2016 , 13, 1016-25	4.7	27
134	Efficacy and safety of LABA/LAMA fixed-dose combinations approved in the US for the management of COPD. <i>Expert Review of Respiratory Medicine</i> , 2016 , 10, 767-80	3.8	7
133	The Responsiveness of the Anxiety Inventory for Respiratory Disease Scale Following Pulmonary Rehabilitation. <i>Chest</i> , 2016 , 150, 188-95	5.3	16
132	Age-Related Differences in Health-Related Quality of Life in COPD: An Analysis of the COPDGene and SPIROMICS Cohorts. <i>Chest</i> , 2016 , 149, 927-35	5.3	25
131	Lebrikizumab in the treatment of asthma. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 847-852	5.4	4
130	The asthma COPD overlap syndrome (ACOS). <i>Current Allergy and Asthma Reports</i> , 2015 , 15, 509	5.6	46
129	Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 27-34	4.7	98
128	Executive summary: prevention of acute exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. <i>Chest</i> , 2015 , 147, 883-893	5.3	44
127	Antifungals in severe asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2015 , 21, 48-54	3	14
126	Role of anticholinergics in asthma management: recent evidence and future needs. <i>Current Opinion in Pulmonary Medicine</i> , 2015 , 21, 103-8	3	6
125	Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. <i>Thorax</i> , 2015 , 70, 748-56	7.3	291
124	Hospital management of acute exacerbations of chronic obstructive pulmonary disease. <i>Journal of Hospital Medicine</i> , 2015 , 10, 328-39	2.7	10
123	A review of the most common patient-reported outcomes in COPD--revisiting current knowledge and estimating future challenges. <i>International Journal of COPD</i> , 2015 , 10, 725-38	3	35
122	Implications of Marijuana Decriminalization on the Practice of Pulmonary, Critical Care, and Sleep Medicine. A Report of the American Thoracic Society Marijuana Workgroup. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 1700-10	4.7	16

121	Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. <i>Chest</i> , 2015 , 147, 894-942	5.3	169
120	Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma. <i>Journal of Biological Chemistry</i> , 2014 , 289, 12623-32	5.4	51
119	Omaliuzumab in asthma: an update on recent developments. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014 , 2, 525-36.e1	5.4	145
118	A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation. <i>Respiratory Medicine</i> , 2014 , 108, 1310-20	4.6	10
117	Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications. <i>Therapeutic Advances in Chronic Disease</i> , 2014 , 5, 212-27	4.9	86
116	Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD. <i>Respiratory Medicine</i> , 2014 , 108, 366-75	4.6	21
115	Efficacy and Safety of Lebrikizumab in Severe Uncontrolled Asthma: Results from the Lute and Verse Phase II Randomized, Double-Blind, Placebo-Controlled Trials. <i>Journal of Allergy and Clinical Immunology</i> , 2014 , 133, AB402	11.5	14
114	One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. <i>Chest</i> , 2014 , 146, 1531-1542	5.3	20
113	A simplified score to quantify comorbidity in COPD. <i>PLoS ONE</i> , 2014 , 9, e114438	3.7	44
112	The Saudi guidelines for chronic obstructive pulmonary disease: A fresh "Real-World" approach to COPD. <i>Annals of Thoracic Medicine</i> , 2014 , 9, 53-4	2.2	2
111	Periostin, a novel biomarker of TH2-driven asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2014 , 20, 60-5		77
110	Optimizing care of your patients with COPD. <i>Nursing (Auckland, N Z)</i> , 2014 , 7	1	
109	Comorbidities of COPD have a major impact on clinical outcomes, particularly in African Americans. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2014 , 1, 105-114	2.7	32
108	Exploring the effects of omaliuzumab in allergic asthma: an analysis of biomarkers in the EXTRA study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 187, 804-11	10.2	609
107	Racial differences in CT phenotypes in COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013 , 10, 20-7	2	27
106	Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. <i>Lancet Respiratory Medicine</i> , 2013 , 1, 210-23	35.1	249
105	Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2013 , 132, 1295-302	11.5	224
104	Age-related differences in asthma outcomes in the United States, 1988-2006. <i>Annals of Allergy, Asthma and Immunology</i> , 2013 , 110, 240-6, 246.e1	3.2	39

103	Ten years of tiotropium: clinical impact and patient perspectives. <i>International Journal of COPD</i> , 2013 , 8, 117-25	3	27
102	Comparative effectiveness of noninvasive ventilation vs invasive mechanical ventilation in chronic obstructive pulmonary disease patients with acute respiratory failure. <i>Journal of Hospital Medicine</i> , 2013 , 8, 165-72	2.7	27
101	Asthma outcomes revisited. <i>Current Opinion in Pulmonary Medicine</i> , 2013 , 19, 6-12	3	4
100	Perceptions and attitudes toward the use of nebulized therapy for COPD: patient and caregiver perspectives. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013 , 10, 482-92	2	21
99	Evaluating the safety of COPD medications: an evidence-based review. <i>Chest</i> , 2013 , 144, 1357-1367	5.3	4
98	The safety of long-acting β_2 -agonists in the treatment of stable chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2013 , 8, 53-64	3	39
97	Optimizing safety of COPD treatments: role of the nurse practitioner. <i>Journal of Multidisciplinary Healthcare</i> , 2013 , 6, 53-63	2.8	8
96	Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. <i>Respiratory Medicine</i> , 2012 , 106, 91-101	4.6	67
95	The effects of cigarette smoke on airway inflammation in asthma and COPD: therapeutic implications. <i>Respiratory Medicine</i> , 2012 , 106, 319-28	4.6	126
94	Examining fatigue in COPD: development, validity and reliability of a modified version of FACIT-F scale. <i>Health and Quality of Life Outcomes</i> , 2012 , 10, 100	3	28
93	Age-related differences in clinical outcomes for acute asthma in the United States, 2006-2008. <i>Journal of Allergy and Clinical Immunology</i> , 2012 , 129, 1252-1258.e1	11.5	112
92	New bronchodilators. <i>Current Opinion in Pharmacology</i> , 2012 , 12, 238-45	5.1	17
91	Effect of a primary care continuing education program on clinical practice of chronic obstructive pulmonary disease: translating theory into practice. <i>Mayo Clinic Proceedings</i> , 2012 , 87, 862-70	6.4	20
90	Targeting IgE in asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2012 , 18, 1-5	3	42
89	A combined pulmonary-radiology workshop for visual evaluation of COPD: study design, chest CT findings and concordance with quantitative evaluation. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2012 , 9, 151-9	2	114
88	A Better Way to Assess Bronchoreversibility: Response. <i>Chest</i> , 2012 , 141, 1118-1119	5.3	1
87	Glucose and pyruvate metabolism in severe chronic obstructive pulmonary disease. <i>Journal of Applied Physiology</i> , 2012 , 112, 42-7	3.7	22
86	The efficacy and safety of the novel long-acting β_2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. <i>Chest</i> , 2012 , 142, 119-127	5.3	83

85	Prevalence of airway obstruction assessed by lung function questionnaire. <i>Mayo Clinic Proceedings</i> , 2011 , 86, 375-81	6.4	15
84	Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease. <i>Respiratory Medicine</i> , 2011 , 105, 1516-22	4.6	56
83	Measuring the impact of a live, case-based, multiformat, interactive continuing medical education program on improving clinician knowledge and competency in evidence-based COPD care. <i>International Journal of COPD</i> , 2011 , 6, 297-307	3	13
82	A unified front against COPD: clinical practice guidelines from the American College of Physicians, the American College of Chest Physicians, the American Thoracic Society, and the European Respiratory Society. <i>Chest</i> , 2011 , 140, 565-566	5.3	16
81	Racial differences in quality of life in patients with COPD. <i>Chest</i> , 2011 , 140, 1169-1176	5.3	42
80	Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. <i>Annals of Internal Medicine</i> , 2011 , 154, 573-82	8	355
79	Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. <i>Annals of Internal Medicine</i> , 2011 , 155, 179-91	8	702
78	Resting energy expenditure and protein turnover are increased in patients with severe chronic obstructive pulmonary disease. <i>Metabolism: Clinical and Experimental</i> , 2011 , 60, 1449-55	12.7	37
77	Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. <i>Respiratory Research</i> , 2011 , 12, 6	7.3	57
76	Gender differences of airway dimensions in anatomically matched sites on CT in smokers. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2011 , 8, 285-92	2	27
75	Clinical and economic burden of depression/anxiety in chronic obstructive pulmonary disease patients within a managed care population. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2011 , 8, 293-9	2	59
74	Lebrikizumab treatment in adults with asthma. <i>New England Journal of Medicine</i> , 2011 , 365, 1088-98	59.2	1213
73	Persistence of effectiveness of bronchial thermoplasty in patients with severe asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2011 , 107, 65-70	3.2	73
72	Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011 , 183, 604-11	10.2	202
71	Safety of chronic obstructive pulmonary disease medications: a primary care perspective. <i>Postgraduate Medicine</i> , 2011 , 123, 72-9	3.7	13
70	Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. <i>Radiology</i> , 2011 , 261, 274-82	20.5	300
69	Pharmacological Therapy: Bronchodilators 2011 , 99-114		
68	Bronchodilator reversibility in COPD. <i>Chest</i> , 2011 , 140, 1055-1063	5.3	60

67	The COPD Pipeline XII. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2011 , 8, 387-91	2	
66	Th2 lymphocyte potassium channels in asthma. <i>FASEB Journal</i> , 2011 , 25, 945.7	0.9	
65	Budesonide/formoterol combination in COPD: a US perspective. <i>International Journal of COPD</i> , 2010 , 5, 357-66	3	19
64	Arformoterol tartrate in the treatment of COPD. <i>Expert Review of Respiratory Medicine</i> , 2010 , 4, 155-62	3.8	5
63	COPD in the elderly patient. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2010 , 31, 596-606	3.9	41
62	beta-Adrenoceptor inverse agonists in asthma. <i>Current Opinion in Pharmacology</i> , 2010 , 10, 254-9	5.1	36
61	Predicting risk of airflow obstruction in primary care: Validation of the lung function questionnaire (LFQ). <i>Respiratory Medicine</i> , 2010 , 104, 1160-70	4.6	49
60	The safety and efficacy of arformoterol and formoterol in COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2010 , 7, 17-31	2	19
59	Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism. <i>Current Opinion in Pulmonary Medicine</i> , 2010 , 16, 1-5	3	39
58	Asthma in the elderly: current knowledge and future directions. <i>Current Opinion in Pulmonary Medicine</i> , 2010 , 16, 55-9	3	35
57	Development of the Lung Function Questionnaire (LFQ) to identify airflow obstruction. <i>International Journal of COPD</i> , 2010 , 5, 1-10	3	43
56	Cognitive-behavioral therapy for chronic cardiopulmonary conditions: preliminary outcomes from an open trial. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2010 , 12,		22
55	Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 2435-40	11.5	92
54	Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease. <i>Advances in Therapy</i> , 2009 , 26, 1024-34	4.1	7
53	Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial. <i>Drugs</i> , 2009 , 69, 1205-16	12.1	28
52	The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. <i>Pulmonary Pharmacology and Therapeutics</i> , 2008 , 21, 134-41	3.5	102
51	One hundred years of respiratory medicine chronic obstructive pulmonary disease (COPD) Republished article. <i>Respiratory Medicine: COPD Update</i> , 2008 , 4, 8-25		3
50	Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study. <i>Clinical Therapeutics</i> , 2008 , 30 Spec No, 989-1002	3.5	15

49	The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD. <i>Pulmonary Pharmacology and Therapeutics</i> , 2008 , 21, 540-50	3.5	40
48	It's about time--directing our attention toward modifying the course of COPD. <i>Respiratory Medicine</i> , 2008 , 102 Suppl 1, S37-48	4.6	6
47	Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial. <i>Therapeutic Advances in Respiratory Disease</i> , 2008 , 2, 199-208	4.9	17
46	Evaluation of obstructive lung disease with vibration response imaging. <i>Journal of Asthma</i> , 2008 , 45, 923-30	1.9	13
45	Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2008 , 5, 25-34	2	33
44	Targeting airway inflammation in asthma: current and future therapies. <i>Chest</i> , 2008 , 133, 989-98	5.3	61
43	Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. <i>Chest</i> , 2008 , 134, 43S-56S	5.3	455
42	Bronchodilators: Beta2-Agonists and Anticholinergics 2008 , 241-250		
41	Update on the pharmacologic therapy for chronic obstructive pulmonary disease. <i>Clinics in Chest Medicine</i> , 2007 , 28, 589-607, vi-vii	5.3	7
40	Asthma in older adults. <i>Clinics in Chest Medicine</i> , 2007 , 28, 685-702, v	5.3	33
39	Revisiting asthma control: how should it best be defined?. <i>Pulmonary Pharmacology and Therapeutics</i> , 2007 , 20, 483-92	3.5	7
38	The role of intrinsic efficacy in determining response to a beta2-agonist in acute severe asthma. <i>Respiratory Medicine</i> , 2007 , 101, 1007-14	4.6	23
37	One hundred years of chronic obstructive pulmonary disease (COPD). <i>Respiratory Medicine</i> , 2007 , 101, 1049-65	4.6	34
36	Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. <i>Clinical Therapeutics</i> , 2007 , 29, 261-78	3.5	54
35	Optimizing maintenance therapy for chronic obstructive pulmonary disease: strategies for improving patient-centered outcomes. <i>Clinical Therapeutics</i> , 2007 , 29, 2121-33	3.5	8
34	Salmeterol stimulation dissociates beta2-adrenergic receptor phosphorylation and internalization. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2007 , 36, 254-61	5.7	47
33	Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. <i>Proceedings of the American Thoracic Society</i> , 2007 , 4, 526-34		53
32	Influenza vaccine in patients with asthma. <i>Expert Review of Vaccines</i> , 2006 , 5, 111-8	5.2	3

31	Predicting episodes of poor asthma control in treated patients with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2006 , 118, 1226-33	11.5	69
30	A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. <i>American Journal of Emergency Medicine</i> , 2006 , 24, 259-67	2.9	41
29	The role of combination therapy with corticosteroids and long-acting beta2-agonists in the prevention of exacerbations in COPD. <i>International Journal of COPD</i> , 2006 , 1, 345-54	3	11
28	The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. <i>Clinical Therapeutics</i> , 2005 , 27, 531-42	3.5	22
27	Treatments for COPD. <i>Respiratory Medicine</i> , 2005 , 99 Suppl B, S28-40	4.6	21
26	Ipratropium Bromide HFA. <i>Treatments in Respiratory Medicine</i> , 2005 , 4, 221-222		
25	Acute asthma in pregnancy. <i>Critical Care Medicine</i> , 2005 , 33, S319-24	1.4	35
24	Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease. <i>Current Opinion in Internal Medicine</i> , 2005 , 11, 129-34		17
23	The challenge of differentiating asthma from chronic obstructive pulmonary disease. <i>Managed Care</i> , 2005 , 14, 9-15; discussion 24-6	0.3	2
22	Anti-inflammatory activities of beta2-agonists. <i>Inflammation and Allergy: Drug Targets</i> , 2004 , 3, 271-7		34
21	Acute asthma in pregnancy. <i>Critical Care Clinics</i> , 2004 , 20, 731-45, x	4.5	28
20	Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy. <i>Journal of Allergy and Clinical Immunology</i> , 2004 , 113, 717-24	11.5	70
19	Differentiating Asthma and COPD Patients. <i>Chest</i> , 2004 , 126, 654-655	5.3	2
18	The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. <i>Chest</i> , 2003 , 124, 834-43	5.3	283
17	Beta-agonist intrinsic efficacy: measurement and clinical significance. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002 , 165, 1353-8	10.2	99
16	Inhaled Salmeterol/Fluticasone Propionate Combination in Chronic Obstructive Pulmonary Disease. <i>Treatments in Respiratory Medicine</i> , 2002 , 1, 283-283		1
15	Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy. <i>Leukemia and Lymphoma</i> , 2002 , 43, 423-6	1.9	76
14	Pulmonary-renal syndromes in the intensive care unit. <i>Critical Care Clinics</i> , 2002 , 18, 881-95, x	4.5	13

13	Accidental hypothermia. <i>Critical Care Clinics</i> , 1999 , 15, 235-49	4.5	44
12	Vasodilators in mechanical ventilation. <i>Critical Care Clinics</i> , 1998 , 14, 611-27	4.5	19
11	Ventilation of patients with asthma and obstructive lung disease. <i>Critical Care Clinics</i> , 1998 , 14, 685-705	4.5	18
10	The Rational Use of β_2 -Agonists in the Management of Asthma: Maintenance, Rescue, and Emergency. <i>Seminars in Respiratory and Critical Care Medicine</i> , 1998 , 19, 613-624	3.9	5
9	Effect of exposure to low levels of ozone on the response to inhaled allergen in allergic asthmatic patients. <i>Chest</i> , 1998 , 114, 752-6	5.3	20
8	Factors associated with emergency department dependence of patients with asthma. <i>Chest</i> , 1997 , 111, 290-5	5.3	58
7	The accuracy of a handheld portable spirometer. <i>Chest</i> , 1996 , 109, 152-7	5.3	38
6	Adverse effects of inhaled corticosteroids. <i>American Journal of Medicine</i> , 1995 , 98, 196-208	2.4	195
5	Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. <i>Journal of Allergy and Clinical Immunology</i> , 1995 , 96, 571-9	11.5	149
4	Medical Personnel Knowledge of the Ability to Use Inhaling Devices. <i>Chest</i> , 1995 , 107, 290	5.3	2
3	Health-care utilization after near-fatal asthma. <i>Chest</i> , 1995 , 107, 1564-9	5.3	14
2	Medical personnel knowledge of and ability to use inhaling devices. Metered-dose inhalers, spacing chambers, and breath-actuated dry powder inhalers. <i>Chest</i> , 1994 , 105, 111-6	5.3	190
1	Acute Lung Injury and Acute Respiratory Distress Syndrome (ARDS) During Pregnancy	338-347	